Compare AbCellera Biologics Inc (ABCL) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Illinois Tool Works Inc. — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Illinois Tool Works Inc. trades at $265.44 (market cap $77.99B). The key difference: Illinois Tool Works Inc. is far larger — about 33.2× AbCellera Biologics Inc's market cap, and Illinois Tool Works Inc. pays a 2.38% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ITW | |
|---|---|---|
Market Cap | $2.35B | $77.99B |
Sector | Health | Industrials |
52-Week High | $8.12 | $299.60 |
52-Week Low | $2.78 | $241.07 |
Enterprise Value | $1.99B | $86.31B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ITW trades at $271.09, down 0.61% on the day, with a bullish technical signal from moving averages and ADX indicators. The company maintains strong profitability with a 19.32% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights product upgrades from its Miller Electric division and a declared quarterly dividend of $1.61.
Outlook remains positive with raised 2026 EPS guidance, though valuation ratios like P/E of 25.47 suggest premium pricing. Risks include high debt levels and sensitivity to industrial demand cycles. Analyst consensus price target of $284.50 implies modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
